Identifying new biological markers for lung disease in cystic fibrosis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to identify new biological markers by characterizing the immune response and inflammation associated with Mycobacterium abscessus lung disease in cystic fibrosis patients. The main objective is to evaluate the correlation between early changes in specific cell populations and soluble immunity activation proteins with the progression of lung disease. Secondary objectives include identifying cellular expression profiles and biomarkers that can predict clinical outcomes, as well as expanding knowledge on the disease's progression. The study utilizes advanced techniques such as Luminex and single-cell RNA sequencing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.
* Both sexes
* Age \>18 years
* Obtaining informed consent for patients (based on the procedures established by the protocol).

Exclusion Criteria:

* Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.

Where it's running

• Ospedale San Raffaele
  Milan, Mi, Italy Recruiting

Study contacts

• Study coordinator: Nicola I Lorè, PhD
• Email: lore.nicolaivan@hsr.it
• Phone: +390226434902

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cellular markers for non-tuberculous mycobacterial infection in adults with cystic fibrosis

  This test will try a blood-based IGRA that measures T-cell interferon-gamma response to help detect NTM infection in adults with cystic fibrosis.

  Recruiting University Hospital, Montpellier · Montpellier · NCT06602869

• Registry to collect data on mycobacterial infections in Austria

  This study is collecting information from patients in Austria with mycobacterial infections to see how their treatment goes and what factors might affect their recovery.

  Recruiting at 3 sites Ludwig Boltzmann Institute for Lung Health · Vienna and 2 other locations · NCT06522347

• Creating a database for patients with bronchiectasis and NTM in Canada

  This study is creating a database to gather information from adults with bronchiectasis and NTM to help improve care and understanding of these conditions.

  Recruiting University of Calgary · Calgary, Alberta · NCT06144996

• Investigational gene therapy for adults with cystic fibrosis

  This study is testing a new gene therapy for adults with cystic fibrosis who have severe lung disease and can't use current treatments, to see if it helps improve their health.

  Recruiting at 18 sites Phase 2 4D Molecular Therapeutics · Birmingham, Alabama and 19 other locations · NCT05248230

• Using breath analysis to identify multiple lung diseases

  This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.

  Recruiting ChromX Health · Guangzhou, Guangdong · NCT06528418

• Observing the progression of cystic fibrosis lung disease in young patients

  This study looks at how lung disease develops in young children with cystic fibrosis to see if early diagnosis and treatment make a difference.

  Recruiting at 4 sites Heidelberg University · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT02270476

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.